<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615991</url>
  </required_header>
  <id_info>
    <org_study_id>CIMS-2012-01</org_study_id>
    <nct_id>NCT01615991</nct_id>
  </id_info>
  <brief_title>Multicentre Canadian Study to Measure the Safety and Efficacy of Radiosynoviorthesis</brief_title>
  <acronym>RSO</acronym>
  <official_title>Multicentre Canadian Study to Measure the Safety and Efficacy of Synoviorthesis Performed With Yttrium-90 or Rhenium-186 Sulfide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation synovectomy by intra-articular injection of beta-emitting radionuclides is&#xD;
      considered a reliable and easy-to-perform therapy without harmful side-effects for the&#xD;
      treatment of inflammatory joint disease in many countries.&#xD;
&#xD;
      The goal of this study is to demonstrate Yttrium-90 citrate colloid or Rhenium-186 sulfide&#xD;
      synovectomy are appropriate therapeutic interventions in patients with persistent active&#xD;
      synovitis of a joint (characterized by pain, tenderness, and effusion) which is resistant to&#xD;
      systemic therapy and intra-articular corticosteroid injections.&#xD;
&#xD;
      The primary objective will be to assess the safety of an intra-articular administration of&#xD;
      Yttrium-90 citrate colloid or Rhenium-186 sulfide.&#xD;
&#xD;
      The secondary objective will be to assess the efficacy on synovitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 31, 2012</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>3-4 days post -treatment</time_frame>
    <description>The safety profile will be assessed by the incidence of AEs. All the AEs will be described by system/organ class and preferred terms and overall sorted by frequency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Clinical response post treatment</time_frame>
    <description>Efficacy outcomes will be the clinical response over 1 year post treatment ( at 3, 6 and 12 months):The comparison will be done with a confidence interval approach based on a Chi²-test for each of the above secondary criterion assessed at different times during the follow-up compared to the same criterion assessed at baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>radiosynoviorthesis with yttrium-90 or rhenium -186</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients suffering from arthritis or chronic inflammatory joint disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiosynoviorthesis</intervention_name>
    <description>Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint</description>
    <arm_group_label>radiosynoviorthesis with yttrium-90 or rhenium -186</arm_group_label>
    <other_name>Yttrium-90 colloid suspension for local injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  There is no age limit for RSO&#xD;
&#xD;
          -  Patient referred by a medical joint specialist (orthopedist, rheumatologist or&#xD;
             internal medicine in the absence of local joint specialist)&#xD;
&#xD;
          -  Patient having a refractory inflammatory articular disease:&#xD;
&#xD;
          -  Failure of medical therapy after 6 months&#xD;
&#xD;
          -  Clinical signs of an active mono or oligo synovitis&#xD;
&#xD;
          -  Joint X-ray, echo or MR showing minimal cartilage or bone destruction&#xD;
&#xD;
          -  Pain limits normal activities or requires significant analgesic medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior RSO within last 3 months in that joint&#xD;
&#xD;
          -  Collapse of the articular plateau or intra-articular fracture&#xD;
&#xD;
          -  Surgery or arthroscopy within last 6 weeks&#xD;
&#xD;
          -  Painful prosthesis&#xD;
&#xD;
          -  Joint infection, local skin infection, bacteremia&#xD;
&#xD;
          -  Joint puncture within last 2 weeks (increased risk of soft tissue necrosis along the&#xD;
             needle track)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Synovial cyst rupture&#xD;
&#xD;
          -  Massive hemarthrosis&#xD;
&#xD;
          -  Generalized synovitis defined as more than 5 uncontrolled joints by clinical&#xD;
             examination or 3 phases bone scan&#xD;
&#xD;
          -  Surgical synovectomy within 6months&#xD;
&#xD;
          -  Cancer with bone metastases&#xD;
&#xD;
          -  Hypersensitivity, allergies or contraindication to the used radiopharmaceutical agent&#xD;
&#xD;
          -  Participation in any other ongoing clinical trial for the underlying inflammatory&#xD;
             condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Turcotte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lion's Gate Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V7L 2L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de santé et services sociaux Pierre-Boucher, Hôpital Pierre-Boucher</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Trois-Rivières</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Québec</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Dr Éric E Turcotte, MD</investigator_full_name>
    <investigator_title>Head, Clinical research, Centre d'imagerie moléculaire de Sherbrooke; Associate Professor, Université de Sherbrooke;Nuclear Medecine Specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

